Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BLIMP-1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses.

Immunology and cell biology·2026

Same author

Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4<sup>+</sup> T cells.

Nature communications·2026

Same author

Efferocytosis of apoptotic bodies drives SARS-CoV-2 infection and macrophage inflammation.

Nature communications·2026

Same author

Cas9-expressing HC-04 hepatocytes facilitate CRISPR-based analysis of Plasmodium falciparum sporozoite-host interactions.

PLoS genetics·2026

Same author

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Trials·2026

Same author

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Viruses·2026

Search research articles

Related Experiment Video

Updated: Jun 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Current State of Therapeutics for HTLV-1.

Tiana T Wang¹, Ashley Hirons², Marcel Doerflinger^3,4

¹Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.

|October 26, 2024

Summary

Human T cell leukaemia virus type-1 (HTLV-1) causes lifelong infections and associated diseases like ATL and HAM. This review explores novel gene therapy and vaccine strategies for HTLV-1, offering hope for effective treatments.

Keywords:

ATL HAM HTLV-1 antiviral therapeutics retrovirus

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Area of Science:

Virology
Immunology
Gene Therapy

Background:

Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus causing lifelong infections in millions globally.
HTLV-1 is endemic in specific populations and leads to severe immune-related disorders like adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM).
Current treatments for HTLV-1 infection are limited and primarily manage symptoms, highlighting the urgent need for new therapeutic interventions.

Purpose of the Study:

To review current and past therapeutic and vaccine development efforts for HTLV-1 infection.
To explore the potential of gene therapy as a novel treatment modality for HTLV-1, drawing parallels with successes in Human Immunodeficiency Virus Type-1 (HIV-1) treatment.
To discuss the role of animal models in advancing novel antiviral and anticancer interventions for HTLV-1.

Main Methods:

Literature review of past and ongoing research in HTLV-1 therapeutics and vaccines.
Analysis of recent advances in RNA-based antiviral therapeutics for analogous retroviruses like HIV-1.
Examination of gene therapy successes and their applicability to HTLV-1 treatment.

Main Results:

Significant progress has been made in developing RNA-based therapeutics for retroviral infections.
Gene therapy shows promise as a potential new treatment modality for HTLV-1.
Animal models are crucial for advancing novel antiviral and anticancer interventions.

Conclusions:

The lack of effective treatments for HTLV-1 necessitates the exploration of alternative strategies.
Gene therapy, inspired by HIV-1 research, offers a promising avenue for HTLV-1 treatment development.
Continued research utilizing animal models is essential for developing effective HTLV-1 interventions.